Valuation: Adaptive Biotechnologies Corporation

Market Cap 3.9B 3.38B 3.17B 2.89B 5.44B 373B 5.53B 37.35B 14.58B 186B 14.66B 14.34B 622B P/E 2026 *
-44.9x
P/E 2027 * -138x
Enterprise Value 3.78B 3.28B 3.08B 2.8B 5.28B 361B 5.36B 36.21B 14.14B 181B 14.21B 13.9B 603B EV / Sales 2026 *
12.9x
EV / Sales 2027 * 10.4x
Free-Float
98.52%
Yield 2026 *
-
Yield 2027 * -
1 day-3.13%
1 week+3.64%
Current month+8.37%
1 month+16.37%
3 months+86.29%
6 months+52.49%
Current year+50.62%
1 week 24.41
Extreme 24.41
26.16
1 month 20.9
Extreme 20.9
26.16
Current year 12
Extreme 12
26.16
1 year 11.92
Extreme 11.92
26.16
3 years 2.28
Extreme 2.28
26.16
5 years 2.28
Extreme 2.28
40
10 years 2.28
Extreme 2.28
71.25
Manager TitleAgeSince
Chief Executive Officer 51 08/09/2009
Director of Finance/CFO 42 08/04/2024
President 54 01/02/2018
Director TitleAgeSince
Chairman 51 -
Director/Board Member 63 01/02/2013
Director/Board Member 70 01/12/2013
Date Insider Type Main position Quantity % Market Cap.
10/08/26 Sell

Executive/Senior Manager

-3,000 0.0019%
30/07/26 Sell

Executive/Senior Manager

-1,299 0.0008%
21/07/26 Fiscal year

Founder

1,062,000 0.6636%
Change 5-day change 1-year change 3-year change Capi.($)
-3.13%+3.64%+88.15%+288.25% 3.9B
-4.66%-7.69%+38.85%+69.38% 3.42B
-3.26%+4.99%+166.12%-7.65% 2.95B
+0.15%+5.74%+290.60%+432.36% 2.45B
+3.97%+10.19%-19.73%-28.79% 2.39B
-0.16%+11.15%+13.73%+44.02% 1.02B
0.00%-7.52%+110.18%-44.10% 861M
+0.75%+9.89%-35.73%-0.10% 567M
-6.71%-7.26%-24.22%+246.22% 473M
+17.18%+28.79%+76.67% - 268M
Average +0.41%+4.86%+70.46%+111.07% 1.83B
Weighted average by Cap. -1.43%+2.33%+94.51%+136.03%

Financials

2026 *2027 *
Net sales 293M 254M 238M 217M 409M 27.99B 415M 2.81B 1.1B 14.01B 1.1B 1.08B 46.73B 359M 311M 291M 266M 500M 34.22B 508M 3.43B 1.34B 17.13B 1.35B 1.32B 57.14B
Net income -85.78M -74.35M -69.7M -63.55M -120M -8.19B -121M -821M -320M -4.1B -322M -315M -13.67B -27.55M -23.88M -22.39M -20.41M -38.41M -2.63B -39.03M -264M -103M -1.32B -103M -101M -4.39B
Net Debt -119M -103M -96.91M -88.36M -166M -11.38B -169M -1.14B -445M -5.7B -448M -438M -19.01B -166M -144M -135M -123M -231M -15.8B -235M -1.58B -618M -7.91B -622M -608M -26.39B
Logo Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
Employees
624
Date Price Change Volume
13/08/26 $24.46 -3.13% 1,537,646
12/08/26 $25.25 -0.55% 1,706,891
11/08/26 $25.39 -0.24% 2,956,649
10/08/26 $25.45 +2.09% 2,366,094
07/08/26 $24.93 +5.64% 2,495,201
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
24.46USD
Average target price
25.07USD
Spread / Average Target
+2.50%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ADPT Stock